US FDA approves expanded use of J&J's cancer cell therapy

FDA allowed the expanded use of Johnson and Johnson Legend Biotech's Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer.

The US Food and Drug Administration on Friday allowed the expanded use of Johnson and Johnson Legend Biotech's Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer.